Clinical Trial Update: Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED) [Phase 2]

View source ↗

Summary

Phase IIb trial updating safety and efficacy across four dose regimens of BAY1021189 in patients with heart failure with preserved ejection fraction (SOCRATES-P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• BAY1021189 (BAY1021189)

Snippet

Sponsor: Bayer | Conditions: Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2021-02-12